---
title: "AQB.US (AQB.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/AQB.US/news.md"
symbol: "AQB.US"
name: "AQB.US"
parent: "https://longbridge.com/en/quote/AQB.US.md"
datetime: "2026-05-21T18:06:51.291Z"
locales:
  - [en](https://longbridge.com/en/quote/AQB.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AQB.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AQB.US/news.md)
---

# AQB.US (AQB.US) — Related News

### [AquaBounty Undertakes Debt Exchange and Preferred Stock Financing](https://longbridge.com/en/news/282041859.md)
*2026-04-08T12:39:57.000Z*
> AquaBounty Technologies, Inc. has exchanged $4 million in senior notes for 236,367 shares of Series A Convertible Prefer

### [12 Health Care Stocks Moving In Monday's Pre-Market Session](https://longbridge.com/en/news/279266196.md)
*2026-03-16T12:05:39.000Z*
> In Monday's pre-market session, several health care stocks experienced significant movements. CytomX Therapeutics (CTMX)

### [Aqua Bio Technology Calls Extraordinary Meeting to Approve Reverse Split and Capital Measures](https://longbridge.com/en/news/273712926.md)
*2026-01-26T14:03:42.000Z*
> Aqua Bio Technology ASA has announced an extraordinary general meeting on February 16, 2026, in Oslo to seek shareholder

### [AquaBounty Technologies Secures $4M in Senior Notes](https://longbridge.com/en/news/263170727.md)
*2025-10-28T21:30:10.000Z*
> AquaBounty Technologies (AQB) has announced the issuance of $4 million in Senior Notes, which are unsecured, nonconverti

### [AquaBounty Tech | 10-Q: FY2025 Q3 Revenue: USD 0](https://longbridge.com/en/news/263091533.md)
*2025-10-28T12:44:27.000Z*
### [AquaBounty Tech | 8-K: FY2025 Q3 Revenue: USD 0](https://longbridge.com/en/news/263080363.md)
*2025-10-28T12:13:44.000Z*
### [U.S. stock market midday update: AquaBounty Tech rises 17.86%](https://longbridge.com/en/news/258390024.md)
*2025-09-22T15:32:52.000Z*
> AquaBounty Tech rose 17.86%; Metsera rose 62.12%, with a transaction volume of USD 572 million; Qualigen Therapeutics ro